SRPK1 and cancer: In addition, while results shown here and elsewhere [19] demonstrated that forced inhibition of SRPK1 using shRNA constructs sensitizes cancer cells to cisplatin treatment in vitro (Figure 3), Schenk et al. have found that down-regulation of SRPK1 with antisense oligodeoxynucleotides in A2780 cells confers resistance to cisplatin [43].